Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03487666
Title	OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Georgetown University
Indications	triple-receptor negative breast cancer
Therapies	Capecitabine + Nivolumab Capecitabine Nivolumab
Age Groups:	adult \| senior
Covered Countries	USA

Filter rows:

Showing 1 to 4 of 4 entries

Facility	City	State	Zip	Country	Details
John Theurer Cancer Center at Hackensack University Medical Center	Hackensack	New Jersey	07601	United States	Details
MedStar Georgetown University Hospital	Washington	District of Columbia	20007	United States	Details
MedStar Washington Hospital Center	Washington	District of Columbia	20010	United States	Details
University of Chicago	Chicago	Illinois	60637	United States	Details

Showing 1 to 4 of 4 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field